Modeling and Cost Benefit Analysis to Guide Deployment of POC Diagnostics for Non-typhoidal Salmonella Infections with Antimicrobial Resistance.
Africa South of the Sahara
/ epidemiology
Anti-Bacterial Agents
/ pharmacology
Bacteremia
/ diagnosis
Child
Cost-Benefit Analysis
Disease Outbreaks
/ economics
Drug Resistance, Bacterial
Health Care Costs
Humans
Microbial Sensitivity Tests
/ economics
Models, Economic
Point-of-Care Systems
/ economics
Salmonella
/ drug effects
Salmonella Infections
/ diagnosis
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 08 2019
02 08 2019
Historique:
received:
05
01
2018
accepted:
05
07
2019
entrez:
4
8
2019
pubmed:
4
8
2019
medline:
11
11
2020
Statut:
epublish
Résumé
Invasive non-typhoidal Salmonella (NTS) is among the leading causes of blood stream infections in sub-Saharan Africa and other developing regions, especially among pediatric populations. Invasive NTS can be difficult to treat and have high case-fatality rates, in part due to emergence of strains resistant to broad-spectrum antibiotics. Furthermore, improper treatment contributes to increased antibiotic resistance and death. Point of care (POC) diagnostic tests that rapidly identify invasive NTS infection, and differentiate between resistant and non-resistant strains, may greatly improve patient outcomes and decrease resistance at the community level. Here we present for the first time a model for NTS dynamics in high risk populations that can analyze the potential advantages and disadvantages of four strategies involving POC diagnostic deployment, and the resulting impact on antimicrobial treatment for patients. Our analysis strongly supports the use of POC diagnostics coupled with targeted antibiotic use for patients upon arrival in the clinic for optimal patient and public health outcomes. We show that even the use of imperfect POC diagnostics can significantly reduce total costs and number of deaths, provided that the diagnostic gives results quickly enough that patients are likely to return or stay to receive targeted treatment.
Identifiants
pubmed: 31375759
doi: 10.1038/s41598-019-47359-2
pii: 10.1038/s41598-019-47359-2
pmc: PMC6677775
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
11245Références
Sci Rep. 2017 Aug 22;7(1):9113
pubmed: 28831084
J Clin Microbiol. 2011 Feb;49(2):671-6
pubmed: 21106789
Clin Infect Dis. 2001 Jan 15;32(2):263-9
pubmed: 11170916
Environ Microbiol Rep. 2017 Oct;9(5):635-641
pubmed: 28677342
Lancet. 2012 Jun 30;379(9835):2489-2499
pubmed: 22587967
Bull Math Biol. 2010 Aug;72(6):1506-33
pubmed: 20143271
J Theor Biol. 2008 Sep 7;254(1):178-96
pubmed: 18572196
Trop Med Int Health. 2009 Dec;14(12):1467-74
pubmed: 19793081
PLoS Negl Trop Dis. 2015 Jul 31;9(7):e0003979
pubmed: 26230258
Clin Microbiol Rev. 2015 Oct;28(4):901-37
pubmed: 26180063
J Clin Invest. 2008 Apr;118(4):1553-62
pubmed: 18357343
Clin Infect Dis. 2008 Apr 1;46(7):963-9
pubmed: 18444810
Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S56-68
pubmed: 26933023
Vaccine. 2015 Jun 19;33 Suppl 3:C8-15
pubmed: 25937611
Epidemiol Infect. 2008 Feb;136(2):263-72
pubmed: 17445313
FEMS Immunol Med Microbiol. 2002 Jul 12;33(3):165-71
pubmed: 12110478
AIDS. 2002 Aug 16;16(12):1633-41
pubmed: 12172085
Ann Clin Microbiol Antimicrob. 2009 May 18;8:15
pubmed: 19445730
Pathog Dis. 2016 Nov;74(8):
pubmed: 27765795
Vaccine. 2015 Jun 19;33 Suppl 3:C21-9
pubmed: 25912288
Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S50-5
pubmed: 26933022
Nat Genet. 2012 Nov;44(11):1215-21
pubmed: 23023330
Trop Med Health. 2017 Feb 10;45:3
pubmed: 28194090
PLoS Negl Trop Dis. 2017 Jan 5;11(1):e0005118
pubmed: 28056035
Lancet Glob Health. 2017 Mar;5(3):e310-e323
pubmed: 28193398
Travel Med Infect Dis. 2011 Nov;9(6):263-77
pubmed: 22118951
J Infect Dis. 2014 Jul 1;210(1):56-64
pubmed: 24443544
Vaccine. 2015 Jun 19;33 Suppl 3:C42-54
pubmed: 25921288
Bull World Health Organ. 1971;45(1):53-75
pubmed: 5316853
PLoS Negl Trop Dis. 2013;7(3):e2103
pubmed: 23516651
Clin Infect Dis. 2009 Aug 15;49(4):606-11
pubmed: 19591599
J Theor Biol. 2013 May 7;324:84-102
pubmed: 23333764
Bull World Health Organ. 2011 Sep 1;89(9):640-7
pubmed: 21897484
Clin Infect Dis. 2010 Mar 15;50(6):882-9
pubmed: 20158401
Lancet Infect Dis. 2010 Jun;10(6):417-32
pubmed: 20510282
Trans R Soc Trop Med Hyg. 2015 Nov;109(11):679-89
pubmed: 26396161
Clin Infect Dis. 2004 Apr 15;38 Suppl 3:S142-8
pubmed: 15095183
PLoS Negl Trop Dis. 2011;5(5):e1148
pubmed: 21655353
J Health Popul Nutr. 2004 Sep;22(3):311-21
pubmed: 15609784
J Med Microbiol. 2006 May;55(Pt 5):585-591
pubmed: 16585646
Math Biosci. 2002 Nov-Dec;180:29-48
pubmed: 12387915
Curr Opin Infect Dis. 2011 Oct;24(5):484-9
pubmed: 21844803
BMJ. 2010 Mar 30;340:c1350
pubmed: 20354024
J Theor Biol. 2005 Mar 21;233(2):159-75
pubmed: 15619358
Microbes Infect. 2018 Oct - Nov;20(9-10):589-598
pubmed: 29248635
J Health Popul Nutr. 2004 Sep;22(3):304-10
pubmed: 15609783
BMC Infect Dis. 2011 May 24;11:147
pubmed: 21609455
J Theor Biol. 2014 Sep 7;356:174-91
pubmed: 24801860
mBio. 2015 Sep 22;6(5):e01421-15
pubmed: 26396246
Clin Infect Dis. 2015 Nov 1;61 Suppl 4:S310-6
pubmed: 26449946
Bull World Health Organ. 2003;81(3):197-204
pubmed: 12764516
Ann Clin Microbiol Antimicrob. 2010 Apr 19;9:14
pubmed: 20403166